The curative effect analysis of transurethral plasmakinetic enucleation and resection of the prostate for patients with small and medium-sized benign prostatic hyperplasia
10.3760/cma.j.cn431274-20210926-01022
- VernacularTitle:经尿道前列腺等离子剜除术治疗中小体积良性前列腺增生的疗效分析
- Author:
Kun JIANG
1
;
Haoyong LI
;
Jinzhuo NING
Author Information
1. 武汉大学人民医院泌尿外科，武汉 430060
- Keywords:
Prostatic hyperplasia;
Transurethral resection of prostate;
Transurethral plasmakinetic enucleation and resection of prostate
- From:
Journal of Chinese Physician
2022;24(6):871-874,880
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the efficacy of transurethral plasmakinetic enucleation and resection of the prostate (TUERP) in the treatment of patients with small and medium-sized benign prostatic hyperplasia (BPH) (<60 ml).Methods:102 clinical cases of BPH (volume <60 ml) in Renmin Hospital of Wuhan University from October 2018 to July 2020 were retrospectively analyzed. All cases were treated with TUERP. The International Prostate Symptom Score (IPSS), maximum flow rate (Qmax), postvoid residual volume (PVR) and prostate specific antigen (PSA) were compared before and after operation. Then the operation efficiency, intraoperative blood loss and postoperative complications incidence rate were analyzed.Results:102 patients with BPH successfully completed the operation. The operation time was 34-69(52.8±8.1)min. The change of hemoglobin concentration during the operation was (10.0±4.9)g/L. The volume of prostate resection was 16.5-42(27.8±5.9)g. The postoperative pathology showed that the prostate was nodular hyperplasia. Among 102 patients, 5 patients had transient stress urinary incontinence (4.90%), 4 patients had capsule perforation (3.93%), and 2 patients had urethral stricture (1.96%). There were significant differences in IPSS, Qmax, PVR and PSA with the comparison of preoperation and postoperation (six months) (all P<0.01). Conclusions:Transurethral plasmakinetic enucleation and resection of the prostate is safe and effective in the treatment of patients with small and medium-sized benign prostatic hyperplasia (<60 ml). It has the characteristics of high resection efficiency, less bleeding, low incidence of complications and exact curative effect.
